Revenue growth figures for Karyopharm Therapeutics reflect the financial profile of a commercial-stage biopharmaceutical enterprise marketing oncology products like XPOVIO while advancing clinical pipelines. Quarterly financial disclosures demonstrate evolving top-line performance shaped by commercial sales trajectories across global markets, alongside intermittent contributions from licensing partnerships and international distribution agreements. Overall growth rates respond directly to commercial adoption rates and regulatory label expansions.